First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Lin Xie, Huiting Xu et al.|Nature Medicine|2025Cited by 89
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)Feng Wang, Rui‐Hua Xu, Ming-Ming He et al.|Clinical Cancer Research|2022Cited by 60
SO-17 A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancerF. Wang, Renjie Xu, Junlan Xiao et al.|Annals of Oncology|2022Cited by 5
A phase III study of comparing FOLFOX+/-bevacizumab with FOLFOX+/-bevacizumab+ high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer.Feng Wang, Rui‐Hua Xu, Jian Xiao et al.|Journal of Clinical Oncology|2020Cited by 2
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Lin Xie, Yanqiao Zhang et al.|Nature Medicine|2025Cited by 2